Targets › TPP1
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2027.
Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. (UniProt, O14773)
Open in Phaseline: the race on TPP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| David L Rogers, MD | Cerliponase Alfa Lysosomal N-terminal tripeptidyl peptidase 1 (TPP1) enzyme replacement therapy | TPP1 | Phase 1 | Neuronal Ceroid Lipofuscinosis Type 2 | Mar 2027 |
Neuronal Ceroid Lipofuscinosis Type 2 (1)
protein or peptide (1)
David L Rogers, MD (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.